ARATANA THERAPEUTICS, INC.

Form 4/A

**STOCK** 

FORM **4** 

FORIN	11 44								0	7.11 1 110 1712		
			ND EXCI D.C. 2054		GE C	OMMISSION	OMB Number:	3235-0287				
Check the character of	ger so state	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								January 31, 2005 ed average nours per e 0.5		
Form 5 obligation may con See Institution 1(b).	Filed pu ons Section 17	(a) of the	Public Ut	ility Holo		any A	Act of	e Act of 1934, 1935 or Section	response on	J 0.0		
(Print or Type	Responses)											
Lichter Jay Symbo				Issuer Name <b>and</b> Ticker or Trading bol ATANA THERAPEUTICS, INC.				5. Relationship of Reporting Person(s) to Issuer				
		[PETX]					(Check all applicable)					
(Last)	Last) (First) (Middle) 3. Date of (Month/D			Earliest Transaction				X DirectorX 10% Owner Officer (give title Other (specify				
C/O ARAT INC., 1901 BOULEVA		EUTICS,	07/02/20	•				below)	below)			
			endment, Date Original nth/Day/Year) 013				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table	e I - Non-D	erivative Se	curiti	es Aca	uired, Disposed o	of, or Benefic	cially Owned		
1.Title of Security (Month/Day/Year) Execution I any (Month/Day		med 3. 4. Securities Acquired n Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8)				uired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
GOVAVON				Code V		or (D)	Price			BY LIMITED		
COMMON STOCK	07/02/2013			P	500,000 (1)	A	\$6	4,170,543 (2)	I	PARTNERSHIP (3)		
COMMON								9.025	ĭ	BY LIMITED LIABILITY		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form SEC 1474 (9-02)

I

9,025

LIABILITY

COMPANY (4)

**OMB APPROVAL** 

### Edgar Filing: ARATANA THERAPEUTICS, INC. - Form 4/A

#### displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orNumber	Expiration D	ate	Amou	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Own
	Security				Acquired						Follo
	·				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration		or		
						Exercisable	Date		Number		
					<del></del>				of		
				Code V	(A) (D)				Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Keiationsnips						
	Director	10% Owner	Officer	Other			
Lichter Jay C/O ARATANA THERAPEUTICS, INC. 1901 OLATHE BOULEVARD KANSAS CITY, KS 66103	X	X					

# **Signatures**

/s/ John C. Ayres, Attorney-in-Fact for Jay 02/04/2014 Lichter

> \*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This amended Form 4 is filed solely for the purpose of reporting the shares purchased as reported on Table 1 Line 1.
- The aggregate shares reported reflect a 2-share decrease from the Reporting Person's Form 4 filed on July 3, 2013 as a result of the (2) rounding of Series A, B and C Convertible Preferred Stock which converted into shares of the Issuer's Common Stock on a 1-for-0.601685 basis upon the closing of the Issuer's initial public offering.
- Held by Avalon Ventures IX, L.P. ("Avalon Ventures LP"). The Reporting Person is a managing director of Avalon Ventures LP and (3) shares voting and dispositive power over the shares held by Avalon Ventures LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- Held by Avalon Ventures IX Management, LLC ("Avalon Ventures LLC"). The Reporting Person is a manager of Avalon Ventures LLC (4) and shares voting and dispositive power over the shares held by Avalon Ventures LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Reporting Owners 2

### Edgar Filing: ARATANA THERAPEUTICS, INC. - Form 4/A

#### **Remarks:**

Exhibit List: Exhibit 24 - Power of Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.